UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors

Ron D. Jachimowicz*, Filippo Beleggia, Jörg Isensee, Bhagya Bhavana Velpula, Jonas Goergens, Matias A. Bustos, Markus A. Doll, Anjana Shenoy, Cintia Checa-Rodriguez, Janica Lea Wiederstein, Keren Baranes-Bachar, Christoph Bartenhagen, Falk Hertwig, Nizan Teper, Tomohiko Nishi, Anna Schmitt, Felix Distelmaier, Hermann Josef Lüdecke, Beate Albrecht, Marcus KrügerBjörn Schumacher, Tamar Geiger, Dave S.B. Hoon, Pablo Huertas, Matthias Fischer, Tim Hucho, Martin Peifer, Yael Ziv, H. Christian Reinhardt, Dagmar Wieczorek, Yosef Shiloh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA double-strand break (DSB) repair. The proteasomal shuttle factor UBQLN4 is phosphorylated by ATM and interacts with ubiquitylated MRE11 to mediate early steps of homologous recombination-mediated DSB repair (HRR). Loss of UBQLN4 leads to chromatin retention of MRE11, promoting non-physiological HRR activity in vitro and in vivo. Conversely, UBQLN4 overexpression represses HRR and favors non-homologous end joining. Moreover, we find UBQLN4 overexpressed in aggressive tumors. In line with an HRR defect in these tumors, UBQLN4 overexpression is associated with PARP1 inhibitor sensitivity. UBQLN4 therefore curtails HRR activity through removal of MRE11 from damaged chromatin and thus offers a therapeutic window for PARP1 inhibitor treatment in UBQLN4-overexpressing tumors.

Original languageEnglish
Pages (from-to)505-519.e22
Issue number3
StatePublished - 24 Jan 2019


FundersFunder number
Israel Cancer Research Fund
Gilead Sciences
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Deutsche ForschungsgemeinschaftKFO-286-RP2, KFO-286-CP2, DI1731/2-1, JA2439/1-1
German-Israeli Foundation for Scientific Research and DevelopmentI-65-412.20-2016
Bundesministerium für Bildung und Forschung01ZX1307, 01ZX1406, 01ZX1303, 01ZX1303A, 01GM1211B
Else Kröner-Fresenius-Stiftung2016_Kolleg.19, 2014-A06
Ministerio de Economía y CompetitividadSAF2016-74855-P, SAF2013-43255-P
Israel Science Foundation
Deutsche Krebshilfe1117240


    • DNA damage
    • DNA double-strand break repair
    • UBQLN4 deficiency syndrome
    • cancer
    • genome instability syndrome
    • homologous recombination
    • non-homologous end joining
    • proteasomal degradation
    • targeted cancer therapy
    • ubiquitin


    Dive into the research topics of 'UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors'. Together they form a unique fingerprint.

    Cite this